^
    29d
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    metformin • Romvimza (vimseltinib)
    1m
    A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=48, Recruiting, Deciphera Pharmaceuticals, LLC | N=36 --> 48
    Enrollment change
    |
    Romvimza (vimseltinib)
    2ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Romvimza (vimseltinib)
    3ms
    Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    Romvimza (vimseltinib)
    3ms
    Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    metformin • Romvimza (vimseltinib)
    3ms
    Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (clinicaltrials.gov)
    P1, N=32, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Romvimza (vimseltinib)
    4ms
    Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Romvimza (vimseltinib)
    4ms
    Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New trial • Real-world evidence
    |
    Romvimza (vimseltinib)
    6ms
    Vimseltinib: First Approval. (PubMed, Drugs)
    Vimseltinib received its first approval in February 2025 in the USA for the treatment of TGCT and is under development for the treatment of chronic graft versus host disease. This article summarizes the milestones in the development of vimseltinib leading to this first approval for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
    Review • Journal
    |
    CSF1R (Colony stimulating factor 1 receptor)
    |
    Romvimza (vimseltinib)
    7ms
    Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Romvimza (vimseltinib)
    1year
    A Study to Evaluate Vimseltinib in Adults with Active Chronic Graft-Versus-Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=36, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Romvimza (vimseltinib)
    1year
    A Phase 2 Study to Evaluate Vimseltinib in Adults with Active Chronic Graft-Versus-Host Disease (cGVHD) (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P2 trial
    |
    Romvimza (vimseltinib)